| Previous Close | 227.52 |
| Open | 230.31 |
| Bid | 223.09 x 800 |
| Ask | 228.00 x 800 |
| Day's Range | 223.62 - 230.31 |
| 52 Week Range | 177.05 - 276.69 |
| Volume | 3,453,588 |
| Avg. Volume | 2,530,755 |
| Market Cap | 129.906B |
| Beta (5Y Monthly) | 0.73 |
| PE Ratio (TTM) | 18.27 |
| EPS (TTM) | 12.31 |
| Earnings Date | Apr. 28, 2021 - May 03, 2021 |
| Forward Dividend & Yield | 7.04 (3.13%) |
| Ex-Dividend Date | Feb. 11, 2021 |
| 1y Target Est | 254.24 |
- Reuters
AstraZeneca-Amgen drug could widen treatment options for severe asthma
AstraZeneca and Amgen's experimental drug reduced asthma attacks in patients with severe and uncontrolled forms of the respiratory condition in a large study, showing promise for wider use against different triggers. The medicine, tezepelumab, cut the rate of asthma attacks by 56% among patients when compared to placebo in a year-long late-stage study, which had roughly 1,000 patients who were already receiving standard care, the drugmakers said on Friday. It also worked in a subgroup of volunteers with low levels of eosinophils, a type of white blood cell, detailed data presented at a virtual meeting of the American Academy of Allergy Asthma and Immunology showed.
- Motley Fool
Why Turning Point Is Turning Heads
This oncology biotech is up over 450% since its April 2019 IPO. Are there still gains to come, or should investors turn away?
- Zacks
Lilly (LLY) COVID-19 Antibody Combo Gets FDA's Emergency Nod
FDA grants EUA to Eli Lilly's (LLY) COVID-19 antibody cocktail. FDA also authorizes shortened infusion time for bamlanivimab/etesevimab.
